Asprius Lifesciences, a Gujarat-based pharmaceutical company, has developed a new treatment for diabetic neuropathy, a condition that causes nerve damage in the peripheral areas of the body. The company has filed a patent for the treatment, which is a fixed-dose combination (FDC) of two drugs.